Why It's Essential to Understand JAK Inhibitors and Their Role in Dermatology—JAK1, JAK2, JAK3, and TYK2s

Faculty
Learning Objectives
Intended Audience
Accreditation Statement
Credit Designation Statement
Disclosure
Disclaimer

Mark Lebwohl, MD

Faculty

Dean for Clinical Therapeutics
Waldman Professor and Chairman
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Upon completion of this activity, the participant should be better able to:

Understand the pathology of immune related diseases in dermatology
Be familiar with the current and emerging JAK inhibitor therapies
Discern the clinical relevance of and differences between the JAK inhibitors, especially TYK2 blockers, with an emphasis on safety and efficacy
Recognize the clinical pros and cons of different JAK-inhibitor therapies for patients with psoriasis and other related immune-related diseases

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients with immune related diseases in dermatology.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nevada, Reno School of Medicine and Dermatology University. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Nevada Reno School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.

This CME activity is supported by an educational grant from Bristol-Myers Squibb.

Faculty Disclosures

Mark Lebwohl

Consultant: Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, Boehringer-Ingelheim, Bristol-Myers Squibb, Cora therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO, meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/ Dr. Reddy’s abs, Theravance, Verrica

Grant/Research Support: Abbvie, Amgen, Arcutis, AstraZeneca, Boehringer Ingelheim, Celgene, Clinuvel, Eli Lilly, Incyte, Janssen Research & Development, Kadmon Corp., LEO, Medimmune, Novartis, Ortho Dermatologics, Pfizer, Sciderm UCB, ViDac

[fc+220]